Premium
A consequence of drug targeting of aminoacyl‐tRNA synthetases in Mycobacterium tuberculosis
Author(s) -
Ndagi Umar,
Kumalo Hezekiel M.,
Mhlongo Ndumiso N.
Publication year - 2021
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.13865
Subject(s) - tuberculosis , mycobacterium tuberculosis , aminoacyl trna synthetase , drug , drug discovery , biology , transfer rna , medicine , pharmacology , biochemistry , rna , pathology , gene
Abstract Drug‐resistant Mycobacterium tuberculosis poses a great threat to public health and remains one of the red‐flag tagged infectious diseases, with the tendency of comorbidity with other disease conditions such as HIV/AIDS. This perhaps is responsible for redoubling of effort in tuberculosis research and continuous change in patient management to optimize the drug therapy. Aminoacyl‐tRNA synthetases are essential enzymes in M. tuberculosis that catalyse the transfer of a particular amino acid to its corresponding specific tRNA to form an aminoacyl‐tRNA. These enzymes are believed to be novel antibacterial, antifungal and antiparasitic drug targets because of their role in the process of protein translation. Therefore, their existence as a compliment of M. tuberculosis has attracted a lot of research interest with the aim of curbing the scourge and provide the most effective drug in the treatment of tuberculosis. This leads to the discovery of a pool of aminoacyl‐tRNA synthetases with their essential inhibitors. This review seeks to articulate the current advances in the development of new TB drugs exhibiting novelty in their mode of action with specific emphasis on aminoacyl‐tRNA synthetases as drug targets.